王妙婵

Superior diagnostic efficacy and cost advantage of FibroTouch over CHI3L1 for liver fibrosis in Chinese patients with chronic liver disease

Background Non-invasive assessment of liver fibrosis is essential for managing chronic liver disease (CLD). Serum chitinase-3-like protein 1 (CHI3L1) has been recommended in recent guidelines, while FibroTouch is a domestically produced device for liver stiffness measurement (LSM...